With top­i­cal ap­proval, Der­ma­vant looks to bring new stan­dard-of-care to plaque pso­ri­a­sis pa­tients

Der­ma­vant CEO Todd Za­vod­nick has been plot­ting to up­end the plaque pso­ri­a­sis mar­ket for years now. And with the com­pa­ny’s first ap­proval on Tues­day, he’s pulling the trig­ger.

The FDA on Tues­day ap­proved Der­ma­vant’s “cos­met­i­cal­ly el­e­gant” van­ish­ing cream tap­inarof, the first steroid-free top­i­cal med­ica­tion in its class, now mar­ket­ed as Vta­ma. And un­like oth­er launch­es, which could take months, Za­vod­nick is ready to roll it out as ear­ly as next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER